JP2018503380A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018503380A5 JP2018503380A5 JP2017537510A JP2017537510A JP2018503380A5 JP 2018503380 A5 JP2018503380 A5 JP 2018503380A5 JP 2017537510 A JP2017537510 A JP 2017537510A JP 2017537510 A JP2017537510 A JP 2017537510A JP 2018503380 A5 JP2018503380 A5 JP 2018503380A5
- Authority
- JP
- Japan
- Prior art keywords
- cdr
- seq
- region
- nos
- sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001413 amino acids Chemical group 0.000 claims 70
- 239000012634 fragment Substances 0.000 claims 47
- 239000000427 antigen Substances 0.000 claims 34
- 102000036639 antigens Human genes 0.000 claims 34
- 108091007433 antigens Proteins 0.000 claims 34
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 10
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 9
- 102000004169 proteins and genes Human genes 0.000 claims 9
- 108090000623 proteins and genes Proteins 0.000 claims 9
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims 7
- 102000049583 human ROR1 Human genes 0.000 claims 7
- 230000004068 intracellular signaling Effects 0.000 claims 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 4
- 102000016978 Orphan receptors Human genes 0.000 claims 4
- 108070000031 Orphan receptors Proteins 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 101100038118 Mus musculus Ror1 gene Proteins 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 2
- 230000000139 costimulatory effect Effects 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 208000004736 B-Cell Leukemia Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 208000024313 Testicular Neoplasms Diseases 0.000 claims 1
- 206010057644 Testis cancer Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 201000005188 adrenal gland cancer Diseases 0.000 claims 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010536 head and neck cancer Diseases 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000000050 myeloid neoplasm Diseases 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000003120 testicular cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562104664P | 2015-01-16 | 2015-01-16 | |
| US62/104,664 | 2015-01-16 | ||
| PCT/US2016/013808 WO2016115559A1 (en) | 2015-01-16 | 2016-01-18 | Antibodies and chimeric antigen receptors specific for ror1 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021004675A Division JP2021061857A (ja) | 2015-01-16 | 2021-01-15 | Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018503380A JP2018503380A (ja) | 2018-02-08 |
| JP2018503380A5 true JP2018503380A5 (https=) | 2019-02-28 |
| JP6865688B2 JP6865688B2 (ja) | 2021-04-28 |
Family
ID=55272713
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017537510A Active JP6865688B2 (ja) | 2015-01-16 | 2016-01-18 | Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体 |
| JP2021004675A Pending JP2021061857A (ja) | 2015-01-16 | 2021-01-15 | Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021004675A Pending JP2021061857A (ja) | 2015-01-16 | 2021-01-15 | Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20160208018A1 (https=) |
| EP (2) | EP3245231B1 (https=) |
| JP (2) | JP6865688B2 (https=) |
| KR (1) | KR20170128234A (https=) |
| CN (1) | CN107428833B (https=) |
| AR (1) | AR103442A1 (https=) |
| AU (1) | AU2016206457B2 (https=) |
| CA (1) | CA2973964A1 (https=) |
| ES (1) | ES2818103T3 (https=) |
| MX (2) | MX2017009254A (https=) |
| NZ (1) | NZ733841A (https=) |
| TW (2) | TW202126682A (https=) |
| WO (1) | WO2016115559A1 (https=) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2818103T3 (es) | 2015-01-16 | 2021-04-09 | Juno Therapeutics Inc | Anticuerpos y receptores de antígenos quiméricos específicos para ROR1 |
| PL3298033T5 (pl) | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
| KR102847348B1 (ko) | 2015-11-25 | 2025-08-19 | 주식회사 리가켐바이오사이언스 | 펩타이드 그룹을 포함하는 접합체 및 이와 관련된 제조방법 |
| AU2016359230B2 (en) | 2015-11-25 | 2020-04-23 | Ligachem Biosciences Inc. | Conjugates comprising self-immolative groups and methods related thereto |
| AU2016359235B2 (en) | 2015-11-25 | 2022-09-15 | Ligachem Biosciences Inc. | Antibody-drug conjugates comprising branched linkers and methods related thereto |
| EP4006056A1 (en) | 2016-02-02 | 2022-06-01 | Fred Hutchinson Cancer Research Center | Anti-ror1 antibodies and uses thereof |
| CA3032498A1 (en) | 2016-08-02 | 2018-02-08 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
| WO2018067993A1 (en) | 2016-10-07 | 2018-04-12 | TCR2 Therapeutics Inc. | Compositions and methods for t-cell receptors reprogramming using fusion proteins |
| JP7291396B2 (ja) | 2016-11-22 | 2023-06-15 | ティーシーアール２ セラピューティクス インク． | 融合タンパク質を用いたｔｃｒの再プログラミングのための組成物及び方法 |
| MX2019010906A (es) | 2017-03-14 | 2020-02-12 | Juno Therapeutics Inc | Metodos para almacenamiento criogenico. |
| CA3058360A1 (en) | 2017-03-29 | 2018-10-04 | Legochem Biosciences, Inc. | Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same |
| CN110573177A (zh) | 2017-04-28 | 2019-12-13 | 尤利乌斯·马克西米利安维尔茨堡大学 | 具有人源化靶向结构域的ror1特异性嵌合抗原受体(car) |
| AU2018289581C1 (en) * | 2017-06-23 | 2025-01-30 | VelosBio Inc. | ROR1 antibody immunoconjugates |
| GB201710836D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Car T-Cells |
| GB201710838D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
| GB201710835D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | ROR1 Antibodies |
| KR20260026092A (ko) | 2017-09-19 | 2026-02-25 | 메사추세츠 인스티튜트 오브 테크놀로지 | 키메라 항원 수용체 t 세포 요법을 위한 조성물 및 그의 용도 |
| WO2019060695A1 (en) | 2017-09-22 | 2019-03-28 | Kite Pharma, Inc. | CHIMERIC POLYPEPTIDES AND USES THEREOF |
| PT3703750T (pt) | 2017-11-01 | 2025-01-17 | Memorial Sloan Kettering Cancer Center | Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes |
| JP7550647B2 (ja) | 2018-02-14 | 2024-09-20 | アントレラ セラピューティクス インコーポレイテッド | Ｗｎｔシグナル伝達を活性化する多価結合分子およびその使用 |
| WO2019200347A1 (en) * | 2018-04-13 | 2019-10-17 | Fred Hutchinson Cancer Research Center | Methods for adoptive cell therapy targeting ror1 |
| CA3097369A1 (en) | 2018-04-17 | 2019-10-24 | Celldex Therapeutics, Inc. | Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs |
| SG11202010235QA (en) * | 2018-04-18 | 2020-11-27 | Exelixis Inc | Anti-ror antibody constructs |
| CN112601555A (zh) | 2018-05-09 | 2021-04-02 | 乐高化学生物科学股份有限公司 | 与抗cd19抗体药物结合物相关的组合物和方法 |
| CN108441505B (zh) * | 2018-05-28 | 2023-07-07 | 上海恒润达生生物科技股份有限公司 | 一种靶向ror1的嵌合抗原受体及其用途 |
| CA3105816A1 (en) * | 2018-07-10 | 2020-01-16 | Precigen, Inc. | Ror-1 specific chimeric antigen receptors and uses thereof |
| EP3853254A1 (en) | 2018-09-20 | 2021-07-28 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd123 immunotherapy |
| AU2019346335B2 (en) | 2018-09-28 | 2024-07-25 | Massachusetts Institute Of Technology | Collagen-localized immunomodulatory molecules and methods thereof |
| SG11202107976SA (en) * | 2019-01-29 | 2021-08-30 | Juno Therapeutics Inc | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
| AU2020248448B2 (en) * | 2019-03-26 | 2026-01-29 | The Regents Of The University Of California | Chimeric antigen receptor modified T-cells (CAR-T) for the treatment of hematological and solid tumor cancers |
| WO2020263399A1 (en) | 2019-06-26 | 2020-12-30 | Massachusetts Institute Of Technology | Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof |
| US20220289843A1 (en) * | 2019-08-19 | 2022-09-15 | Elpis Biopharmaceuticals | Anti-cd19 antibodies and uses thereof |
| KR20210028544A (ko) * | 2019-09-04 | 2021-03-12 | 주식회사 레고켐 바이오사이언스 | 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도 |
| WO2021061648A1 (en) | 2019-09-23 | 2021-04-01 | Massachusetts Institute Of Technology | Methods and compositions for stimulation of endogenous t cell responses |
| US12497453B2 (en) | 2019-09-27 | 2025-12-16 | Nanjing Immunophage Biotech Co., Ltd. | ROR1 specific chimeric antigen receptors and their therapeutic applications |
| EP4100438A1 (en) * | 2020-02-07 | 2022-12-14 | Velosbio Inc. | Anti-ror1 antibodies and compositions |
| CA3170023A1 (en) * | 2020-02-27 | 2021-09-02 | Nanjing Legend Biotech Co., Ltd. | Antibodies and chimeric antigen receptors targeting glypican-3 (gpc3) and methods of use thereof |
| BR112022017924A2 (pt) | 2020-03-10 | 2022-12-20 | Massachusetts Inst Technology | Composições e métodos para imunoterapia de câncer npm1c-positivo |
| JP2023517063A (ja) | 2020-03-10 | 2023-04-21 | マサチューセッツ インスティテュート オブ テクノロジー | 操作されたメモリー様ｎｋ細胞を作製するための方法およびその組成物 |
| HRP20240182T1 (hr) | 2020-03-26 | 2024-04-26 | Vanderbilt University | Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2) |
| US20230122364A1 (en) * | 2020-03-27 | 2023-04-20 | Vanderbilt University | HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) |
| MX2022013499A (es) | 2020-04-27 | 2023-01-16 | Twist Bioscience Corp | Bibliotecas de ácidos nucleicos variantes para coronavirus. |
| US12433954B2 (en) | 2020-05-01 | 2025-10-07 | Massachusetts Institute Of Technology | Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs |
| US20210340524A1 (en) | 2020-05-01 | 2021-11-04 | Massachusetts Institute Of Technology | Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof |
| BR112022022953A2 (pt) * | 2020-05-12 | 2023-03-21 | Lyell Immunopharma Inc | Espaçadores de receptores de antígenos quiméricos |
| KR20230152783A (ko) | 2020-07-07 | 2023-11-03 | 칸큐어 엘엘씨 | Mic 항체 및 결합제 및 이의 사용 방법 |
| EP4209509A4 (en) * | 2020-09-03 | 2025-03-19 | Harbour Biomed (Shanghai) Co., Ltd | ROR1-TARGETTING ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, METHOD OF PREPARATION THEREOF AND USE THEREOF |
| EP4240756A1 (en) | 2020-11-04 | 2023-09-13 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
| CA3204321A1 (en) | 2020-12-18 | 2022-06-23 | Antlera Therapeutics Inc. | Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof |
| WO2023250402A2 (en) | 2022-06-22 | 2023-12-28 | Antlera Therapeutics Inc. | Tetravalent fzd and wnt co-receptor binding antibody molecules and uses thereof |
| AR124414A1 (es) | 2020-12-18 | 2023-03-22 | Century Therapeutics Inc | Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable |
| KR20230122618A (ko) | 2020-12-21 | 2023-08-22 | 알로젠 테라퓨틱스 인코포레이티드 | 프로테아제 활성화 cd45-게이트 car |
| CN116601168A (zh) * | 2020-12-25 | 2023-08-15 | 电化株式会社 | 靶抗原的测定方法以及用于其的不溶性粒子及靶抗原测定用试剂盒 |
| CA3204417A1 (en) | 2021-01-29 | 2022-08-04 | Allogene Therapeutics, Inc. | Knockdown or knockout of one or more of tap2, nlrc5, ?2m, trac, rfx5, rfxap and rfxank to mitigate t cell recognition of allogeneic cell products |
| US12144827B2 (en) | 2021-02-25 | 2024-11-19 | Lyell Immunopharma, Inc. | ROR1 targeting chimeric antigen receptor |
| CN117693508A (zh) | 2021-03-03 | 2024-03-12 | 朱诺治疗学股份有限公司 | T细胞疗法和dgk抑制剂的组合 |
| JP2024517863A (ja) | 2021-05-06 | 2024-04-23 | ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 細胞を刺激し、形質導入する方法 |
| IL312204A (en) | 2021-10-28 | 2024-06-01 | Lyell Immunopharma Inc | Methods for culturing cells expressing ror1-binding protein |
| US20260083848A1 (en) | 2021-11-03 | 2026-03-26 | Viracta Therapeutics, Inc. | Combination of car t-cell therapy with btk inhibitors and methods of use thereof |
| KR20240125944A (ko) * | 2021-12-28 | 2024-08-20 | 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 | 항-ror1 항체 및 항-ror1 항체 약물 접합체 및 이의 의약적 용도 |
| CN118574845A (zh) * | 2022-01-29 | 2024-08-30 | 杭州中美华东制药有限公司 | 一种靶向ror1的抗体或其抗原结合片段及其应用 |
| US11590169B1 (en) | 2022-03-02 | 2023-02-28 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD123 immunotherapy |
| CA3255500A1 (en) | 2022-04-08 | 2023-10-12 | Regeneron Pharmaceuticals, Inc. | MULTI-PART RECEIVERS AND SIGNALING COMPLEXES |
| US20250297282A1 (en) | 2022-05-05 | 2025-09-25 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
| WO2024008112A1 (en) * | 2022-07-06 | 2024-01-11 | Nona Biosciences (Suzhou) Co., Ltd. | Anti-ror1 antibodies |
| CA3261440A1 (en) | 2022-07-29 | 2024-02-01 | Allogene Therapeutics, Inc. | MODIFIED CELLS WITH REDUCED GENE EXPRESSION TO MITIGATE RECOGNITION BY IMMUNE CELLS |
| EP4583876A1 (en) | 2022-09-08 | 2025-07-16 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
| WO2024064952A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells overexpressing c-jun |
| WO2024064958A1 (en) | 2022-09-23 | 2024-03-28 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| WO2024077174A1 (en) | 2022-10-05 | 2024-04-11 | Lyell Immunopharma, Inc. | Methods for culturing nr4a-deficient cells |
| CN116178567B (zh) * | 2022-10-28 | 2025-01-28 | 四川大学华西医院 | 一种靶向TGFβRII的嵌合抗原受体及其用途 |
| CN120152991A (zh) * | 2022-11-03 | 2025-06-13 | 南京蓬勃生物科技有限公司 | 靶向人源ror1的单域抗体 |
| WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
| JP2026504491A (ja) | 2023-02-03 | 2026-02-05 | ツェー３エス２ ゲーエムベーハー | 操作された免疫細胞の非ウイルス的製造のための方法 |
| TW202444425A (zh) * | 2023-03-23 | 2024-11-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ror1抗體與pbd類化合物的偶聯物、其製備方法及其應用 |
| AU2024372734A1 (en) | 2023-10-30 | 2026-04-16 | Allogene Therapeutics, Inc. | Engineered cells |
| WO2025217398A1 (en) | 2024-04-10 | 2025-10-16 | Lyell Immunopharma, Inc. | Methods for culturing cells with improved culture medium |
| WO2026025092A1 (en) | 2024-07-26 | 2026-01-29 | Juno Therapeutics, Inc. | Synthetic promoters for t cell expression |
| WO2026055308A1 (en) | 2024-09-06 | 2026-03-12 | Merck Sharp & Dohme Llc | Multivalent fzd4, wnt co-receptor, and vegf receptor molecules and uses thereof |
| US20260092125A1 (en) | 2024-09-06 | 2026-04-02 | Eyebiotech Limited | Multivalent fzd4, wnt co-receptor, and vegf binding molecules and uses thereof |
Family Cites Families (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4452773A (en) | 1982-04-05 | 1984-06-05 | Canadian Patents And Development Limited | Magnetic iron-dextran microspheres |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| US4795698A (en) | 1985-10-04 | 1989-01-03 | Immunicon Corporation | Magnetic-polymer particles |
| IN165717B (https=) | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
| US5606040A (en) | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
| US5770701A (en) | 1987-10-30 | 1998-06-23 | American Cyanamid Company | Process for preparing targeted forms of methyltrithio antitumor agents |
| AU4746590A (en) | 1988-12-28 | 1990-08-01 | Stefan Miltenyi | Methods and materials for high gradient magnetic separation of biological materials |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5200084A (en) | 1990-09-26 | 1993-04-06 | Immunicon Corporation | Apparatus and methods for magnetic separation |
| IE913929A1 (en) | 1990-11-13 | 1992-05-20 | Immunex Corp | Bifunctional selectable fusion genes |
| DK0752248T3 (da) | 1992-11-13 | 2000-11-13 | Idec Pharma Corp | Terapeutisk anvendelse af kimæriske og radioaktivt mærkede antistoffer mod humant B-lymfocytbegrænset differentieringsantig |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| AU6953394A (en) | 1993-05-21 | 1994-12-20 | Targeted Genetics Corporation | Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene |
| US5773001A (en) | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US5714586A (en) | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
| US5712374A (en) | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| DE19608753C1 (de) | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
| WO1997034634A1 (en) | 1996-03-20 | 1997-09-25 | Sloan-Kettering Institute For Cancer Research | Single chain fv constructs of anti-ganglioside gd2 antibodies |
| ES2244066T3 (es) | 1997-06-24 | 2005-12-01 | Genentech, Inc. | Procedimiento y composiciones de glicoproteinas galactosiladas. |
| AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| EP1109921A4 (en) | 1998-09-04 | 2002-08-28 | Sloan Kettering Inst Cancer | FUSION RECEPTORS SPECIFIC TO MEMBRANE SPECIFIC PROSTATIC ANTIGEN AND USES THEREOF |
| US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| EP1229125A4 (en) | 1999-10-19 | 2005-06-01 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING A POLYPEPTIDE |
| AU767394C (en) | 1999-12-29 | 2005-04-21 | Immunogen, Inc. | Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use |
| US20020131960A1 (en) | 2000-06-02 | 2002-09-19 | Michel Sadelain | Artificial antigen presenting cells and methods of use thereof |
| PT2281843T (pt) | 2000-06-16 | 2017-01-02 | Human Genome Sciences Inc | Anticorpos que se ligam imunoespecificamente a blys |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| CA2953239A1 (en) | 2000-10-06 | 2002-04-18 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition-producing cell |
| ATE338124T1 (de) | 2000-11-07 | 2006-09-15 | Hope City | Cd19-spezifische umgezielte immunzellen |
| US7070995B2 (en) | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20050232921A1 (en) | 2001-04-13 | 2005-10-20 | Rosen Craig A | Vascular endothelial growth factor 2 |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| NZ571596A (en) | 2001-08-03 | 2010-11-26 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| CA2463879C (en) | 2001-10-25 | 2012-12-04 | Genentech, Inc. | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| AU2003218456A1 (en) | 2002-04-01 | 2003-10-20 | Human Genome Sciences, Inc. | Antibodies that specifically bind to gmad |
| CA2481925A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for patients having human fc.gamma.riiia |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
| EP1500400A4 (en) | 2002-04-09 | 2006-10-11 | Kyowa Hakko Kogyo Kk | MEDICAMENT WITH ANTIBODY COMPOSITION |
| CA2481658A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to fcy receptor iiia |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
| US20050009136A1 (en) | 2003-02-19 | 2005-01-13 | Dyax Corporation | PAPP-A ligands |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| JPWO2005035586A1 (ja) | 2003-10-08 | 2007-11-22 | 協和醗酵工業株式会社 | 融合蛋白質組成物 |
| JPWO2005035778A1 (ja) | 2003-10-09 | 2006-12-21 | 協和醗酵工業株式会社 | α１，６−フコシルトランスフェラーゼの機能を抑制するＲＮＡを用いた抗体組成物の製造法 |
| EP2060270A3 (en) | 2003-10-16 | 2009-12-09 | Imclone LLC | Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof |
| CA2541651C (en) | 2003-10-22 | 2011-05-24 | Keck Graduate Institute | Methods of synthesizing heteromultimeric polypeptides in yeast using a haploid mating strategy |
| US9296820B2 (en) | 2003-11-05 | 2016-03-29 | Roche Glycart Ag | Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function |
| US7435596B2 (en) | 2004-11-04 | 2008-10-14 | St. Jude Children's Research Hospital, Inc. | Modified cell line and method for expansion of NK cell |
| EP2478912B1 (en) | 2003-11-06 | 2016-08-31 | Seattle Genetics, Inc. | Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| US7973139B2 (en) | 2004-03-26 | 2011-07-05 | Human Genome Sciences, Inc. | Antibodies against nogo receptor |
| DK1791565T3 (en) | 2004-09-23 | 2016-08-01 | Genentech Inc | Cysteingensplejsede antibodies and conjugates |
| CL2007002668A1 (es) | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
| SI2856876T1 (en) | 2007-03-30 | 2018-04-30 | Memorial Sloan-Kettering Cancer Center | Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes |
| ES2660180T3 (es) | 2007-12-07 | 2018-03-21 | Miltenyi Biotec Gmbh | Sistemas y métodos para procesamiento de células |
| US8479118B2 (en) | 2007-12-10 | 2013-07-02 | Microsoft Corporation | Switching search providers within a browser search box |
| US20120164718A1 (en) | 2008-05-06 | 2012-06-28 | Innovative Micro Technology | Removable/disposable apparatus for MEMS particle sorting device |
| JP5173594B2 (ja) | 2008-05-27 | 2013-04-03 | キヤノン株式会社 | 管理装置、画像形成装置及びそれらの処理方法 |
| US10611835B2 (en) | 2008-07-10 | 2020-04-07 | Toray Industries, Inc. | Pharmaceutical composition for treatment and prevention of cancer |
| JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
| CA2759733C (en) | 2009-04-23 | 2019-09-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-human ror1 antibodies |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| US9242014B2 (en) * | 2010-06-15 | 2016-01-26 | The Regents Of The University Of California | Receptor tyrosine kinase-like orphan receptor 1 (ROR1) single chain Fv antibody fragment conjugates and methods of use thereof |
| US9163258B2 (en) | 2010-07-23 | 2015-10-20 | Fred Hutchinson Cancer Research Center | Method for the treatment of obesity |
| EP3828205A1 (en) * | 2010-10-01 | 2021-06-02 | Oxford BioTherapeutics Ltd | Anti-ror1 antibodies |
| ES2657970T3 (es) | 2010-12-01 | 2018-03-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anticuerpos contra ROR1 de conejo/ser humano quiméricos |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| GB201020995D0 (en) * | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| US9987308B2 (en) * | 2011-03-23 | 2018-06-05 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| US8398282B2 (en) | 2011-05-12 | 2013-03-19 | Delphi Technologies, Inc. | Vehicle front lighting assembly and systems having a variable tint electrowetting element |
| CN103906532B (zh) | 2011-08-09 | 2018-01-26 | 阿瑟拉生物技术公司 | 结合磷酰胆碱（pc）和/或pc结合物的抗体 |
| MX353958B (es) | 2011-09-22 | 2018-02-07 | Amgen Inc | Proteinas de union al antigeno cd27l. |
| CN104080797A (zh) | 2011-11-11 | 2014-10-01 | 弗雷德哈钦森癌症研究中心 | 针对癌症的靶向细胞周期蛋白a1的t细胞免疫疗法 |
| CA2861491C (en) | 2012-02-13 | 2020-08-25 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| CA3285826A1 (en) | 2012-02-22 | 2026-03-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| WO2013126726A1 (en) | 2012-02-22 | 2013-08-29 | The Trustees Of The University Of Pennsylvania | Double transgenic t cells comprising a car and a tcr and their methods of use |
| EP2844743B1 (en) | 2012-05-03 | 2021-01-13 | Fred Hutchinson Cancer Research Center | Enhanced affinity t cell receptors and methods for making the same |
| BR122020002986A8 (pt) | 2012-08-20 | 2023-04-18 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Método e composições para imunoterapia celular |
| ES2702315T3 (es) * | 2012-08-24 | 2019-02-28 | Univ California | Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis |
| MX370148B (es) | 2012-10-02 | 2019-12-03 | Memorial Sloan Kettering Cancer Center | Composiciones y su uso para inmunoterapia. |
| CN104781789B (zh) | 2012-12-20 | 2018-06-05 | 三菱电机株式会社 | 车载装置 |
| WO2014164554A1 (en) | 2013-03-10 | 2014-10-09 | Baylor College Of Medicine | Chemotherapy-resistant immune cells |
| US9108442B2 (en) | 2013-08-20 | 2015-08-18 | Ricoh Company, Ltd. | Image forming apparatus |
| CN105873952A (zh) | 2013-10-31 | 2016-08-17 | 弗莱德哈钦森癌症研究中心 | 经修饰的造血干细胞/祖细胞和非t效应细胞及其用途 |
| NZ759969A (en) | 2013-12-20 | 2022-12-23 | Fred Hutchinson Cancer Center | Tagged chimeric effector molecules and receptors thereof |
| CN106458154A (zh) | 2014-03-26 | 2017-02-22 | 麦格纳车镜美国有限公司 | 使用投射图标的车辆功能控制系统 |
| US10611837B2 (en) | 2014-04-10 | 2020-04-07 | Seattle Children's Hospital | Transgene genetic tags and methods of use |
| EA035419B9 (ru) | 2014-05-29 | 2020-08-07 | Мэкроудженикс, Инк. | Триспецифичные связывающие молекулы и способы их применения |
| WO2016016344A1 (en) | 2014-07-29 | 2016-02-04 | Cellectis | Ror1(ntrkr1)specific chimeric antigen receptors for cancer immunotherapy |
| HK1243631A1 (zh) | 2014-10-27 | 2018-07-20 | Fred Hutchinson Cancer Research Center | 用於提高过继细胞免疫疗法效力的组合物和方法 |
| ES2818103T3 (es) | 2015-01-16 | 2021-04-09 | Juno Therapeutics Inc | Anticuerpos y receptores de antígenos quiméricos específicos para ROR1 |
| WO2016187216A1 (en) | 2015-05-18 | 2016-11-24 | Bluebird Bio, Inc. | Anti-ror1 chimeric antigen receptors |
| SG11201803098VA (en) | 2015-10-30 | 2018-05-30 | Nbe Therapeutics Ag | Anti-ror1 antibodies |
| EP4006056A1 (en) | 2016-02-02 | 2022-06-01 | Fred Hutchinson Cancer Research Center | Anti-ror1 antibodies and uses thereof |
| CA3024725A1 (en) | 2016-06-06 | 2017-12-14 | Juno Therapeutics, Inc. | Methods for the treatment of b cell malignancies using adoptive cell therapy |
| CN110573177A (zh) | 2017-04-28 | 2019-12-13 | 尤利乌斯·马克西米利安维尔茨堡大学 | 具有人源化靶向结构域的ror1特异性嵌合抗原受体(car) |
| CN107557337B (zh) | 2017-09-15 | 2020-06-26 | 山东兴瑞生物科技有限公司 | 一种抗ror1安全型嵌合抗原受体修饰的免疫细胞及其应用 |
| SG11202107976SA (en) | 2019-01-29 | 2021-08-30 | Juno Therapeutics Inc | Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1) |
-
2016
- 2016-01-18 ES ES16702306T patent/ES2818103T3/es active Active
- 2016-01-18 TW TW109132171A patent/TW202126682A/zh unknown
- 2016-01-18 WO PCT/US2016/013808 patent/WO2016115559A1/en not_active Ceased
- 2016-01-18 CN CN201680016204.1A patent/CN107428833B/zh not_active Expired - Fee Related
- 2016-01-18 EP EP16702306.8A patent/EP3245231B1/en active Active
- 2016-01-18 KR KR1020177022796A patent/KR20170128234A/ko not_active Abandoned
- 2016-01-18 NZ NZ733841A patent/NZ733841A/en unknown
- 2016-01-18 JP JP2017537510A patent/JP6865688B2/ja active Active
- 2016-01-18 MX MX2017009254A patent/MX2017009254A/es unknown
- 2016-01-18 CA CA2973964A patent/CA2973964A1/en active Pending
- 2016-01-18 US US14/997,991 patent/US20160208018A1/en not_active Abandoned
- 2016-01-18 AR ARP160100120A patent/AR103442A1/es unknown
- 2016-01-18 TW TW105101422A patent/TWI718118B/zh not_active IP Right Cessation
- 2016-01-18 AU AU2016206457A patent/AU2016206457B2/en not_active Ceased
- 2016-01-18 EP EP20178573.0A patent/EP3760644A1/en not_active Withdrawn
-
2017
- 2017-07-13 MX MX2021009151A patent/MX2021009151A/es unknown
-
2018
- 2018-06-04 US US15/997,635 patent/US10889652B2/en active Active
-
2020
- 2020-12-14 US US17/121,549 patent/US11919970B2/en active Active
-
2021
- 2021-01-15 JP JP2021004675A patent/JP2021061857A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018503380A5 (https=) | ||
| JP2022518925A5 (https=) | ||
| JP6359372B2 (ja) | ＤＡＲＰｉｎを含む二重特異キメラ蛋白質 | |
| US20190367612A1 (en) | Anti-gprc5d antibody and molecule containing same | |
| JP6681433B2 (ja) | Ｐ２ｘ７受容体アンタゴニスト及びアゴニスト | |
| JP7202185B2 (ja) | 抗ｃｄ３抗体及び該抗体を含む分子 | |
| JP2021508469A5 (https=) | ||
| JP2017526370A5 (https=) | ||
| JP2020501531A5 (https=) | ||
| IL273424B1 (en) | Novel bispecific cd3/cd19 polypeptide complexes | |
| JP2022541435A5 (https=) | ||
| JP2018507188A5 (https=) | ||
| RU2017110044A (ru) | Антитела и химерные антигенные рецепторы, специфичные к cd19 | |
| JP2019533719A5 (https=) | ||
| JP2021525546A5 (https=) | ||
| JP2019524693A5 (https=) | ||
| JP2016512223A5 (https=) | ||
| FI3334765T3 (fi) | Yksidomeenivasta-aineisiin perustuvia kimeerisiä antigeenireseptoreita ja menetelmiä niiden käyttämiseksi | |
| JP2013545738A5 (https=) | ||
| JP2013529059A5 (https=) | ||
| JP2018502050A5 (https=) | ||
| JP2013527762A5 (https=) | ||
| RU2013125457A (ru) | Комбинация антител против с-мет | |
| JP2017512838A5 (https=) | ||
| JP2013520984A5 (https=) |